2023-06-20 08:48:41
Chemotherapy, EGFR-targeted therapy, and immunotherapy are the pillars of lung cancer treatment. By overcoming the blood-brain barrier with second-generation EGFR-directed tyrosine kinase inhibitors, patients with brain metastases can be treated better.
koto_feja/GettyImages
Better patient selection is needed for the use of immunotherapy, and adjuvant EGFR-directed therapy prolongs patient survival. These are important findings presented at this year’s ASCO Annual Meeting in Chicago.
Approximately one-third of patients with non-small cell lung cancer (NSCLC) present with resectable disease. Adjuvant therapy with osimertinib, an EGFR tyrosine kinase inhibitor (EGFR TKI), demonstrated clinical benefit over placebo in the phase III ADAURA study. Overall survival (OS) results were presented at ASCO.1
To see the content you need to log in or register.
1687300196
#Advances #nonsmall #cell #lung #cancer #pleural #mesothelioma
